Dr. Sauter on Off-The-Shelf Versus Autologous CAR T-Cell Products in Hematologic Malignancies

Video

Craig Sauter, MD, discusses the differences between off-the-shelf and autologous chimeric antigen receptor T-cell products in patients with hematologic malignancies.

Craig Sauter, MD, a hematologic oncologist and clinical director of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, discusses the differences between off-the-shelf and autologous chimeric antigen receptor (CAR) T-cell products in patients with hematologic malignancies.

The primary advantage of off-the-shelf CAR T-cell therapy is that patients have the opportunity to access cellular therapy in real time, as compared with autologous products that need to be manufactured in the lab, Sauter says.

Having more immediate access to these products is especially important for patients with poor-risk, relapsed/refractory lymphoma. For these patients, time is a critical component of their care; this is especially true for patients who aren’t responding to therapy, which is the current indication for CAR-modified T cells, Sauter adds.

However, there is a possibility that the off-the-shelf CAR T-cell therapy products can be rejected by the host immune system. Approaches to circumnavigate that risk are currently at the forefront of investigation, Sauter concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.